Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Tomasina, Julie ^a,b,d   Malzert Freon, Aurélie ^a,d   Giffard, Florence ^a,b,c   Brotin, Emilie ^a,b,c   Louis, Marie Hélène ^a,b,c   Abeilard, Edwige ^a,b,c   Rault, Sylvain ^a,d   Gauduchon, Pascal ^a,b   Poulain, Laurent ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c Centre Regional de Lutte Contre le Cancer Baclesse   (France)

^d CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

Apoptosis; Chemoresistance; Ovarian cancer; Tripentone MR22388

Indexed keywords

CISPLATIN; PROTEIN BCL XL; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAUSE OF DEATH; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIZATION;

EID: 84879959747     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-38     Document Type: Article

References (25)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 1 10 29 10.3322/caac.20138 22237781
2. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. Ozols RF, J Clin Oncol 2003 21 2451 2453 10.1200/JCO.2003.03.039 12829660 (Pubitemid 46894005)
3. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Siddik ZH, Oncogene 2003 22 7265 7279 10.1038/sj.onc.1206933 14576837 (Pubitemid 37487159)
4. Molecular mechanisms of resistance and toxicity associated with platinating agents. Rabik CA, Dolan ME, Cancer Treat Rev 2007 33 9 23 10.1016/j.ctrv.2006.09.006 17084534 (Pubitemid 46137553)
5. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L, Gynecol Oncol 2007 105 31 44 10.1016/j.ygyno.2006.12.011 17275076 (Pubitemid 46441466)
6. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, Denoyelle C, Gauduchon P, Poulain L, Mol Cancer Ther 2009 8 11 3162 3170 10.1158/1535-7163. MCT-09-0493 19887550
7. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L, Int J Cancer 2010 126 885 895 19634140
8. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC, Genes Dev 2005 19 11 1294 1305 10.1101/gad.1304105 15901672 (Pubitemid 41003019)
9. Tripentones: a promising series of potent anti-cancer agents. Rochais C, Dallemagne P, Rault S, Anti Cancer Agents Med Chem 2009 9 369 380 10.2174/1871520610909040369
10. MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity. Rochais C, Cresteil T, Perri V, Jouanne M, Lesnard A, Rault S, Dallemagne P, Cancer Lett 2013 331 1 92 98 10.1016/j.canlet.2012.12.017 23268332
11. Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors. Rochais C, Lescot E, Lisowski V, Lepailleur A, Santos JS, Bureau R, Dallemagne P, Meijer L, Rault S, J Enzyme Inhib Med Chem 2004 19 585 593 10.1080/14756360400004565 15662962 (Pubitemid 40057749)
12. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, Staedel C, Int J Cancer 1998 78 454 463 9797134 (Pubitemid 28481164)
13. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K, N'diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L, Apoptosis 2013 Epub ahead of print
14. The xCELLigence system for real-time and label-free monitoring of cell viability. Ke N, Wang X, Xu X, Abassi YA, Methods Mol Biol 2011 740 33 43 10.1007/978-1-61779-108-6-6 21468966
15. Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. Lisowski V, Enguehard C, Lancelot J, Caignard D, Lambel S, Leonce S, Pierre A, Atassi G, Renard P, Rault S, Bioorg Med Chem Lett 2001 11 2205 2208 10.1016/S0960-894X(01)00403-6 11514171 (Pubitemid 32763033)
16. Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. Lisowski V, Léonce S, Kraus-Berthier L, Sopková-de Oliveira Santos J, Pierré A, Atassi G, Caignard DH, Renard P, Rault S, J Med Chem 2004 47 1448 1464 10.1021/jm030961z 14998333 (Pubitemid 38327471)
17. Mcl-1; the molecular regulation of protein function. Thomas LW, Abburi C, Edwards SW, FEBS Lett 2010 584 14 2981 2989 10.1016/j.febslet.2010.05.061 20540941
18. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A, Ichijo H, J Biol Chem 2002 277 43730 43734 10.1074/jbc.M207951200 12223490 (Pubitemid 36157790)
19. Mcl-1. Michels J, Johnson PW, Packham G, Int J Biochem Cell Biol 2005 37 267 271 10.1016/j.biocel.2004.04.007 15474972 (Pubitemid 39330187)
20. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. Basu A, Haldar S, FEBS Lett 2003 538 1-3 41 47 12633850 (Pubitemid 36287422)
21. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC, Gastroenterology 2011 141 2 663 673 10.1053/j.gastro.2011.04.055 21683075
22. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, Chambers TC, J Biol Chem 2008 283 51 35517 35525 10.1074/jbc.M805019200 18974096
23. Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Wang J, Beauchemin M, Bertrand R, Cell Cycle 2012 11 11 2159 2169 10.4161/cc.20672 22617334
24. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Morel C, Carlson SM, White FM, Davis RJ, Mol Cell Biol 2009 29 3845 3852 10.1128/MCB.00279-09 19433446
25. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR, Cancer Cell 2012 21 4 547 562 10.1016/j.ccr.2012.02.028 22516262